Mateus Fernando 4
4 · ABBOTT LABORATORIES · Filed Feb 22, 2023
Insider Transaction Report
Form 4
Mateus Fernando
Senior Vice President
Transactions
- Award
Common shares without par value
2023-02-17+10,560→ 25,063 total - Tax Payment
Common shares without par value
2023-02-21$106.74/sh−664$70,875→ 23,881 total - Award
Option (right to buy)
2023-02-17+41,648→ 41,648 totalExercise: $106.24From: 2024-02-17Exp: 2033-02-16→ Common Shares (41,648 underlying) - Tax Payment
Common shares without par value
2023-02-19$106.74/sh−518$55,291→ 24,545 total
Footnotes (2)
- [F1]These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
- [F2]Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,882 on February 17, 2024, 13,883 on February 17, 2025, and 13,883 on February 17, 2026.